Imunon Says Ovarian Cancer Drug Trial Preliminary Results Show Deeper Antitumor Response

MT Newswires Live07-21

Imunon (IMNN) said Tuesday that preliminary data from its ongoing Phase 2 clinical trial of IMNN-001 showed a deeper antitumor response compared with control in women with newly diagnosed advanced ovarian cancer.

The results showed that the drug, which was conducted in combination with standard of care neoadjuvant and adjuvant chemotherapy plus bevacizumab, demonstrated a lower rate of minimal residual disease and a higher rate of circulating tumor DNA clearance, according to a statement.

The drug also continued to show a highly favorable safety and tolerability profile, the company said.

IMNN-001 is now being evaluated in a phase 3 trial, enrolling patients with newly diagnosed advanced ovarian cancer at clinical sites across the US, Imunon said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2653620331?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-21 21:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2653620331","market":"sg","top_or_hot":-1,"title":"Imunon Says Ovarian Cancer Drug Trial Preliminary Results Show Deeper Antitumor Response","media":"MT Newswires Live","content":"<html><body><p> Imunon (IMNN) said Tuesday that preliminary data from its ongoing Phase 2 clinical trial of IMNN-001 showed a deeper antitumor response compared with control in women with newly diagnosed advanced ovarian cancer.</p><p>The results showed that the drug, which was conducted in combination with standard of care neoadjuvant and adjuvant chemotherapy plus bevacizumab, demonstrated a lower rate of minimal residual disease and a higher rate of circulating tumor DNA clearance, according to a statement.</p><p>The drug also continued to show a highly favorable safety and tolerability profile, the company said.</p><p>IMNN-001 is now being evaluated in a phase 3 trial, enrolling patients with newly diagnosed advanced ovarian cancer at clinical sites across the US, Imunon said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Imunon Says Ovarian Cancer Drug Trial Preliminary Results Show Deeper Antitumor Response</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImunon Says Ovarian Cancer Drug Trial Preliminary Results Show Deeper Antitumor Response\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-21 21:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Imunon (IMNN) said Tuesday that preliminary data from its ongoing Phase 2 clinical trial of IMNN-001 showed a deeper antitumor response compared with control in women with newly diagnosed advanced ovarian cancer.</p><p>The results showed that the drug, which was conducted in combination with standard of care neoadjuvant and adjuvant chemotherapy plus bevacizumab, demonstrated a lower rate of minimal residual disease and a higher rate of circulating tumor DNA clearance, according to a statement.</p><p>The drug also continued to show a highly favorable safety and tolerability profile, the company said.</p><p>IMNN-001 is now being evaluated in a phase 3 trial, enrolling patients with newly diagnosed advanced ovarian cancer at clinical sites across the US, Imunon said.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IMNN","symbol_name":"Imunon, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2653620331","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2653620331","pubTimestamp":1784640998,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Imunon  said Tuesday that preliminary data from its ongoing Phase 2 clinical trial of IMNN-001 showed a deeper antitumor response compared with control in women with newly diagnosed advanced ovarian cancer.The results showed that the drug, which was conducted in combination with standard of care neoadjuvant and adjuvant chemotherapy plus bevacizumab, demonstrated a lower rate of minimal residual disease and a higher rate of circulating tumor DNA clearance, according to a statement.The drug also continued to show a highly favorable safety and tolerability profile, the company said.IMNN-001 is now being evaluated in a phase 3 trial, enrolling patients with newly diagnosed advanced ovarian cancer at clinical sites across the US, Imunon said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IMNN":"Imunon, Inc.","BK4139":"生物科技"},"translate_title":"Imunon 称卵巢癌药物试验初步结果显示更深层的抗肿瘤反应","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMNN":1},"content_text":"Imunon (IMNN) said Tuesday that preliminary data from its ongoing Phase 2 clinical trial of IMNN-001 showed a deeper antitumor response compared with control in women with newly diagnosed advanced ovarian cancer.The results showed that the drug, which was conducted in combination with standard of care neoadjuvant and adjuvant chemotherapy plus bevacizumab, demonstrated a lower rate of minimal residual disease and a higher rate of circulating tumor DNA clearance, according to a statement.The drug also continued to show a highly favorable safety and tolerability profile, the company said.IMNN-001 is now being evaluated in a phase 3 trial, enrolling patients with newly diagnosed advanced ovarian cancer at clinical sites across the US, Imunon said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2653620331","isCrawlerRequest":true}